Sort   by:  
 Page size 
ProteomicsSchlafen 5 as a Novel Therapeutic Target in Pancreatic Ductal Adenocarcinoma
We provide evidence that a member of the human Schlafen (SLFN) family of proteins, SLFN5, is overexpressed in human pancreatic ductal adenocarcinoma (PDAC). Targeted deletion of SLFN5 results in decreased PDAC cell proliferation and suppresses PDAC tumorigenesis in in vivo PDAC models. Importantly, ...
ORGANISM(S): Homo sapiens (Human) 
2021-04-14 | PXD021749 | Pride
Schlafen 5 Pancreatic ductal adenocarcinoma 
ProteomicsULK1 as a novel therapeutic target to enhance immune checkpoint therapies against melanoma
Immune checkpoint inhibitors (ICIs) have transformed the treatment of melanoma. However, the majority of patients have primary or acquired resistance to ICIs, limiting durable responses and patient survival. Interferon-gamma (IFNg) signaling and the expression of IFNg-stimulated genes correlate with...
ORGANISM(S): Homo sapiens (Human) 
2023-02-02 | PXD035347 | Pride
Irf1 Interferon-gamma Ulk1 Melanoma Pd-l1 Signaling Immune checkpoint inhibitors 
ProteomicsTargeting CHAF1B enhances interferon activity in myeloproliferative neoplasms
Interferons (IFNs) are cytokines with potent anti-neoplastic properties and significant clinical activity in the treatment of myeloproliferative neoplasms (MPNs). The use of pegylated IFN for the treatment of MPNs has been of particular interest, with several clinical trials establishing clinical r...
ORGANISM(S): Homo sapiens (Human) 
2023-05-15 | PXD037376 | Pride
Chaf1b Myeloproliferative neoplasms Interferon 
ProteomicsDevelopment of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies
We have developed a novel mTOR pathway inhibitor via targeting SIN1. We used multiple proteomics analyses to determine mechanism of action of our novel Sin1 inhibitor and compare to other mTOR pathway inhibitors.
ORGANISM(S): Homo sapiens (Human) 
2026-01-26 | PXD040952 | Pride
Cancer Drug development Mtor pathway 
ProteomicsDevelopment of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies
We have developed a novel mTOR pathway inhibitor via targeting SIN1. We used multiple proteomics analyses to determine mechanism of action of our novel Sin1 inhibitor and compare to other mTOR pathway inhibitors.
ORGANISM(S): Homo sapiens (Human) 
2026-01-26 | PXD040955 | Pride
Cancer Drug development Mtor pathway 
Sort   by:  
 Page size